Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Value Line Q1 EPS $0.47 Down From $0.62 YoY

Value Line Q1 EPS $0.47 Down From $0.62 YoY

Value Line (NASDAQ:VALU) reported quarterly earnings of $0.47 per share. This is a 24.19 percent decrease over earnings of $0.62 per share from the same period last year.

byBenzinga Newsdesk

September 14, 2022

1 minute read

Value Line (NASDAQ:VALU) reported quarterly earnings of $0.47 per share. This is a 24.19 percent decrease over earnings of $0.62 per share from the same period last year.

Earnings

Earnings Preview: Anheuser-Busch InBev

By Benzinga Insights

October 30, 10:00 AM

Anheuser-Busch InBev (NYSE:BUD) is set to give its latest quarterly earnings report on Tuesday, 2023-10-31. Here’s what investors…

BUD

News

Occidental Petroleum Says Late Dec. 2022 North American Winter Storm Elliott Resulted In Third Party, Co. Operated Downtime; Says While Normal Operations Have Resumed, Avg Permian, Rockies Production In Q4 Expected To Be Impacted By Combined 10 Mboe/Da…

By Michael Horton

January 4, 6:08 PM

-Reuters

OXY

FDA Approves Expanded Use Of Bristol Myers Squibb’s Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma

By Vandana Singh

May 16, 11:56 AM

FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.

BMY